ms win
week review biotech coverag univers end week vs
nbi ytd vs nbi
notabl end week concern around soliri us ip amgn
ipr institut end week acquir otezla
note event week
increas pt acquir otezla celg/bmi
view high price paid potenti thesis-chang acquisit see
note
amgn ipr petit challeng valid soliri us patent institut
ptab though note low bar institut ipr process highlight major
soliri patient switch ultomiri possibl biosimilar entri us market
see note
gmab gmab report top-lin posit result two studi evalu ofatumumab
relaps multipl sclerosi see potenti superior efficacy/safeti profil
ocrevu full data ectrim see note
highlight week
amgn/regn week delawar district court judg overturn portion prior juri verdict
initi found favor sever patent claim repatha link juri verdict note
rule week judg found amgn patent claim overli broad invalid
base lack enabl rule keep regn praluent market
repatha opportun remain substanti investor expect negat
major impact either compani even success abl edg
 market continu domin market script august
total sale vs basi
 announc eu approv soliri treatment adult nmosd patient
antibodi follow posit opinion chmp june
capit disclos stake recent file
last week gsk submit j-nda daprodustat japan treatment anemia
ckd patient follow mitsibushi tanab develop partner japan applic
vadadustat last quarter link note addit fgen roxadustat approv china
treatment anemia ndd-ckd patient follow chines approv dialysis-depend
dd ckd dec
neulasta trx biosimilar fulphila trx
udenyca overal cgrp increas among
aimovig trx decreas ajovi decreas
week emgal increas overal trx
w/w script repatha class competitor
praluent
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
repatha praluent
dupix
cabometyx trx compar favor overal tki
trx
auryxia trx
detail analysi pleas see joint noteworthi weekli rx trend note
drug price track drug price chang coverag week
ssiem symposium read-through
valuat risk
valu dcf basi use wacc termin growth rate
assum trade discount valu forward price-to-earnings basi vs peer similar
growth prospect discount project revenu market product contribut
discount risk-adjust revenu pipelin product contribut
revenu contribut net cash contribut result price
target support sector perform rate
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
exhibit weekli ytd perform
weekli perform trade near high obsv prqr trade near
companytickerratingcurrentpriceptweekli returnytd jone industri nyse arca biotechnolog nasdaq biotechnolog ishar nasdaq biotechnolog specul risk exhibit drug price tracker
compani report pricerx capit market estim
